UVA researchers zero in on new bone marrow cancer treatment

Charlottesville, Va.-based UVA Cancer Center researchers discovered how cancerous bone marrow cells promote the development of myelofibrosis, opening the door to a new treatment option.

Researchers identified a cytokine called interleukin-1 that contributes to the progression of myelofibrosis. Targeting this cytokine can prevent myelofibrosis and spare bone marrow from the scarring that is a hallmark of the disease.

The discovery not only provides a new treatment approach, but sheds light on the fundamental mechanisms of progression of myeloproliferative neoplasms, according to a Nov. 9 UVA release.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars